Global Orphan Drugs Market Size, Share, Trends, And Forecast 2026-2034 Market To Reach USD 589.2 Billion As Genomics, Precision Medicine, And Regulatory Incentives Drive Growth

(MENAFN- GlobeNewsWire - Nasdaq) Maximize ROI through regulatory incentives, rare oncology pipelines, strategic partnerships, AI-led discovery, precision medicine and hospital pharmacy channels

Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Orphan Drugs Market Size, Share, Trends and Forecast by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region, 2026-2034" has been added to ResearchAndMarkets.com's offering.

The global orphan drugs market was valued at USD 261.0 Billion in 2025 and is projected to reach USD 589.2 Billion by 2034, expanding at a CAGR of 9.47% from 2026-2034. North America led the market in 2025 with a 35.5% share, supported by favorable regulatory policies, advanced healthcare infrastructure, strong research capabilities, and continued investment in rare disease treatments.

Global orphan drugs market growth is being driven by greater awareness of rare diseases, advances in genomics and precision medicine, improved diagnostic technologies, and government incentives for pharmaceutical innovation. Regulatory benefits such as market exclusivity, tax credits, fee waivers, research grants, and accelerated approval pathways reduce development risks and encourage investment in treatments for small patient populations with significant unmet medical needs.

Approximately 300 million people worldwide were estimated to be living with rare diseases in 2024. Patient registries, epidemiological research, advocacy organizations, and public awareness campaigns are improving disease recognition and supporting earlier diagnosis. These developments are expanding the identifiable patient population and increasing demand for targeted orphan therapies.

Technology and Regulatory Trends

Genomic sequencing, bioinformatics, companion diagnostics, and personalized medicine are reshaping rare disease diagnosis and drug development. These technologies enable pharmaceutical and biotechnology companies to identify genetic markers, improve patient selection, and develop treatments aligned with specific disease mechanisms. Innovation is particularly strong in biologics, gene therapies, cell-based medicines, monoclonal antibodies, and ribonucleic acid (RNA)-based treatments. The companion diagnostics market is forecast to reach USD 22.3 Billion by 2033, further supporting targeted drug development.

Government funding also contributes to market expansion. In India, plans were announced to establish a National Fund for Rare Diseases (NFRD), with proposed funding of?974 crore for FYs 2024-25 and 2025-26, subject to Ministry of Health and Family Welfare clearance. Comparable or higher funding has been proposed for 2026-27 and 2027-28.

United States Orphan Drugs Market

The United States accounts for 93.00% of the North American market. Growth is supported by the Orphan Drug Act, expedited regulatory reviews, market exclusivity, favorable reimbursement practices, private and public research funding, and an estimated rare disease population exceeding 30 million people.

In 2025, the US Food and Drug Administration awarded orphan drug status to rilzabrutinib, an experimental oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD). Pharmaceutical investment also remains active, with 25 private equity deals announced in the US pharmaceutical industry during Q3 2024, representing a combined value of USD 2.3 Billion.

Orphan Drugs Market Segmentation

• Drug type: Biological and Non-Biological
• Disease type: Oncology, Hematology, Neurology, Cardiovascular, and Others
• Development phase: Phase I, Phase II, Phase III, and Phase IV
• Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others

Biological therapies represented 65.8% of the market in 2025. Their leadership reflects the growing use of monoclonal antibodies, recombinant proteins, gene therapies, and cell-based treatments for complex genetic, immunological, metabolic, and oncological conditions. Strong development pipelines and regulatory mechanisms such as fast-track approval and orphan designation continue to support this segment.

Oncology accounted for 36.6% of the market, making it the leading disease category. Demand is driven by the need for targeted treatments for rare cancers, including specific leukemias, lymphomas, and sarcomas. Advances in immunotherapy, biomarker-led research, and molecular biology are accelerating the development of therapies for uncommon cancer subtypes.

Keytruda held 15.7% of the market among top-selling drugs. The PD-1 inhibitor is used for several oncology indications, including rare cancers such as Merkel cell carcinoma and primary mediastinal large B-cell lymphoma. Other prominent products include Revlimid, Rituxan, Copaxone, Opdivo, Imbruvica, Avonex, Sensipar, and Soliris.

Hospital pharmacies accounted for 48.2% of orphan drug distribution. Their leading position is supported by the specialized administration, monitoring, inventory management, and reimbursement requirements associated with many high-cost rare disease therapies.

Regional Orphan Drugs Market Outlook

• North America: The region benefits from established regulatory incentives, advanced genomic capabilities, strong biotechnology activity, and collaboration among pharmaceutical companies, universities, patient organizations, and government agencies.
• Asia Pacific: Market growth is supported by rising cancer incidence, expanding healthcare infrastructure, increased clinical research, and greater investment in targeted treatments. India recorded an estimated 14,61,427 incident cancer cases in 2022.
• Europe: Research funding, biopharmaceutical innovation, and streamlined regulatory frameworks are advancing orphan drug development. The European Union spent €381 Billion on research and development in 2023, equivalent to 2.22% of GDP.
• Latin America: Digital pharmacies, telemedicine, greater internet penetration, and expanding online distribution are improving access to specialized medicines.
• Middle East and Africa: Healthcare investment, hospital expansion, regulatory development, and new research initiatives are strengthening diagnosis and treatment access. Dubai reported 4,482 private medical facilities and 55,208 licensed healthcare professionals in 2022.

Competitive Landscape

Competition in the global orphan drugs market is intensifying as pharmaceutical and biotechnology companies pursue strategic partnerships, mergers and acquisitions (M&A), licensing agreements, and research collaborations. Investment priorities include gene therapy, immunotherapy, precision medicine, AI-powered drug discovery, and rare oncology. Partnerships between specialty biotechnology companies and large pharmaceutical groups are helping combine early-stage innovation with clinical development, regulatory, manufacturing, and commercialization capabilities.

Leading companies operating in the orphan drugs market include Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca, Bayer AG, Daiichi Sankyo Company Limited, Genentech USA, Inc (F. Hoffmann-La Roche AG), GSK plc, Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceuticals U.S.A., Inc.

With sustained regulatory support, improved rare disease diagnosis, growing therapeutic pipelines, and rapid progress in precision medicine, the global orphan drugs market is positioned for strong expansion through 2034.

Key Attributes

Report Attribute	Details
No. of Pages	144
Forecast Period	2025-2034
Estimated Market Value (USD) in 2025	$261 Billion
Forecasted Market Value (USD) by 2034	$589.2 Billion
Compound Annual Growth Rate	9.4%
Regions Covered	Global

Key Topics Covered
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Orphan Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Biological
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Non-Biological
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Disease Type
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hematology
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Neurology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cardiovascular
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Phase
8.1 Phase I
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Phase II
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Phase III
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Phase IV
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Top Selling Drugs
9.1 Revlimid
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Rituxan
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Copaxone
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Opdivo
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Keytruda
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Imbruvica
9.6.1 Market Trends
9.6.2 Market Forecast
9.7 Avonex
9.7.1 Market Trends
9.7.2 Market Forecast
9.8 Sensipar
9.8.1 Market Trends
9.8.2 Market Forecast
9.9 Soliris
9.9.1 Market Trends
9.9.2 Market Forecast
9.10 Others
9.10.1 Market Trends
9.10.2 Market Forecast
10 Market Breakup by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Retail Pharmacies
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Stores
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Alexion Pharmaceuticals Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Amgen Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 AstraZeneca
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Bayer AG
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Daiichi Sankyo Company Limited
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 Genentech USA, Inc (F. Hoffmann-La Roche AG)
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 SWOT Analysis
16.3.7 GSK plc
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Johnson & Johnson
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Merck & Co., Inc.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Novartis Pharmaceuticals Corporation
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Pfizer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Sanofi S.A.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Takeda Pharmaceuticals U.S.A., Inc
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials
16.3.13.4 SWOT Analysis
List of Figures [110]
List of Tables [9]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06102026004107003653ID1111769577